Transgene

Stocks

Market Closed - Euronext Paris 23:55:00 05/10/2026 HKT			5-day change	1st Jan Change
0.7280 ^EUR	+4.00%		-0.27%	-24.17%

09-25	Transgene provides update on its operations
09-08	Transgene Expands ProBioGen Partnership With Additional License	MT

Published on 11/15/2025 at 12:20 am HKT - Modified on 11/15/2025 at 02:35 am HKT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the Transgene conference call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

09-25	Transgene provides update on its operations
09-08	Transgene Expands ProBioGen Partnership With Additional License	MT
09-03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
09-03	Transgene: no cases of recurrence at three years among patients treated with TG4050
09-03	Transgene And NEC Corporation Report 100% Three-Year Disease-Free Survival With TG4050 And Publish Phase 1 Results In Nature Communications	CI
06-29	Transgene SA - Special Call
06-25	Oddo BHF Stays Positive on Transgene
06-25	Positive Preclinical Data for a Transgene Vaccine
06-25	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
06-22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
06-22	Transgene launches a clinical trial evaluating TG4070 with nivolumab
06-22	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
05-22	Transgene SA Announces Board Appointments	CI
04-13	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI
04-07	Transgene stands out following licensing agreement with NEC Bio

Duration

Period

Sector